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Aims To investigate if recent technical and procedural developments in percutaneous coronary intervention (PCI)
significantly influence outcomes in appropriately selected patients with three-vessel (3VD) coronary artery disease.
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Methods
and results
The SYNTAX II study is a multicenter, all-comers, open-label, single arm study that investigated the impact of a
contemporary PCI strategy on clinical outcomes in patients with 3VD in 22 centres from four European countries.
The SYNTAX-II strategy includes: heart team decision-making utilizing the SYNTAX Score II (a clinical tool com-
bining anatomical and clinical factors), coronary physiology guided revascularisation, implantation of thin strut bio-
resorbable-polymer drug-eluting stents, intravascular ultrasound (IVUS) guided stent implantation, contemporary
chronic total occlusion revascularisation techniques and guideline-directed medical therapy. The rate of major
adverse cardiac and cerebrovascular events (MACCE [composite of all-cause death, cerebrovascular event, any
myocardial infarction and any revascularisation]) at one year was compared to a predefined PCI cohort from the
original SYNTAX-I trial selected on the basis of equipoise 4-year mortality between CABG and PCI. As an explora-
tory endpoint, comparisons were made with the historical CABG cohort of the original SYNTAX-I trial. Overall
708 patients were screened and discussed within the heart team; 454 patients were deemed appropriate to
undergo PCI. At one year, the SYNTAX-II strategy was superior to the equipoise-derived SYNTAX-I PCI cohort
(MACCE SYNTAX-II 10.6% vs. SYNTAX-I 17.4%; HR 0.58, 95% CI 0.39–0.85, P= 0.006). This difference was driven
by a significant reduction in the incidence of MI (HR 0.27, 95% CI 0.11–0.70, P= 0.007) and revascularisation
(HR 0.57, 95% CI 0.37–0.9, P= 0.015). Rates of all-cause death (HR 0.69, 95% CI 0.27–1.73, P= 0.43) and stroke
(HR 0.69, 95% CI 0.10–4.89, P= 0.71) were similar. The rate of definite stent thrombosis was significantly lower in
SYNTAX-II (HR 0.26, 95% CI 0.07–0.97, P= 0.045).
...................................................................................................................................................................................................
Conclusion At one year, clinical outcomes with the SYNTAX-II strategy were associated with improved clinical results com-
pared to the PCI performed in comparable patients from the original SYNTAX-I trial. Longer term follow-up is
awaited and a randomized clinical trial with contemporary CABG is warranted.
...................................................................................................................................................................................................
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Introduction
Percutaneous coronary interventions (PCI) were introduced
40 years ago and became the standard of care for patients with non-
complex coronary artery disease (CAD) not responding to optimal
medical therapy.1 Despite the improved efficacy of PCI with drug
eluting stents (DES), in patients with three-vessel (3VD) CAD, sur-
gery remains the recommended revascularization modality in
patients with intermediate or high anatomical complexity.1 Among
several trials comparing coronary artery bypass graft (CABG) surgery
with PCI in patients with 3VD, the pivotal SYNergy between percutane-
ous coronary intervention with TAXus and cardiac surgery (SYNTAX) trial
identified CABG as the preferred revascularization strategy, com-
pared with PCI with first-generation drug-eluting stents (DES). In the
3VD cohort, PCI was associated with a higher rate of all cause death,
myocardial infarction, and repeat revascularization at 5 years.2
Subsequently, the superiority of CABG over PCI, with first-
generation DES, was confirmed in patients with diabetes in the
FREEDOM trial.3 Recently, in the BEST trial, comparing CABG with
PCI in 3VD using newer generation DES, the 5-year clinical outcomes
were inferior amongst patients who underwent PCI.4
Outcomes of patients with complex CAD are dependent on the
anatomical complexity and patient’s individual clinical characteristics
and comorbidities.5 In appropriately selected patients with less com-
plex 3VD or high surgical risk, PCI may be considered by the heart
team as an acceptable alternative. The SYNTAX Score II is a clinical
tool that combines anatomical and clinical factors to aid the heart
team to undertake objective decision-making between CABG and
PCI based on 4-year mortality.6 Accordingly, patients with anatomical
complexities, including those exceeding the low SYNTAX score
group, are potentially appropriate for either therapy provided there
is equipoise for projected 4-year mortality between CABG and PCI.
Furthermore, advances in PCI [including intracoronary physiology to
assess the appropriateness of revascularization, the advent of thin
strut DES, intravascular imaging guided stent implantation and optimi-
zation, new techniques for revascularization of chronic total occlu-
sions (CTO), and potent dual antiplatelet therapy] have been shown
to improve patients’ outcomes.7–11 We hypothesized that the use of
these PCI technologies, coupled with refined patient selection, could
lead to a marked improvement in outcomes of 3VD patients treated
with PCI.
The present study reports the 1-year clinical follow-up of the
SYNTAX II trial, which was initiated to explore how the integration
of new developments in PCI practice may potentially improve patient
outcomes, compared with the results obtained in the original
SYNTAX-I trial.
Methods
Study design
SYNTAX II is a multicentre, all-comers, open label, single-arm study
which included patients with de novo 3VD. Patients were enrolled in 22
interventional cardiology centres from four European countries between
February 2014 and November 2015 (Supplementary material online,
Table S1). The study design has been described previously.12 Briefly,
patients with de novo 3VD with no left main involvement were screened
by the local heart team (interventional cardiologist and cardiac surgeon).
All site reported, anatomical SYNTAX scores, were eligible for initial
Results of the SYNTAX II study 3125
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.screening.13 Eligible patients had a SYNTAX score II (site-reported) with
an equipoise recommendation between CABG and PCI based on 4-year
mortality. In addition, patients were asked to volunteer only if the local
heart team judged that an ‘equivalent anatomical revascularisation’ based
on a vessel size of 1.5 mm could potentially be achieved.14
SYNTAX II was an investigator-initiated study, sponsored by the
European Cardiovascular Research Institute (ECRI, Rotterdam, the
Netherlands) with unrestricted research grants from Volcano and
Boston Scientific. The grant givers were not involved in data collection,
data interpretation or writing the manuscript. The local Ethics committee
approved the study in all participating sites.
Procedural characteristics
Target lesions were assessed using a hybrid coronary physiology
approach [Instantaneous wave-free ratio (Volcano Corporation) and
fractional flow reserve (iFR/FFR)] to define the appropriateness of revas-
cularization based on the presence of ischaemia. An iFR <0.86 indicated
need for revascularization, an iFR between 0.86 and 0.93 required deci-
sion making based on FFR, and an iFR >0.93 indicated deferral of PCI.12
The SYNERGY DES (Boston Scientific, Natick, MA, USA) was implanted
according to routine local clinical practice. Pre-PCI intravascular ultra-
sound (IVUS) was used at the discretion of the operator. Post-PCI IVUS
assessment (site-reported) was mandatory to optimize stent expansion
and apposition following the modified MUSIC criteria (Supplementary
material online, Table S2).15 Treatment of bifurcation lesions was consis-
tent with the European Bifurcation Club’s consensus.16 Revascularization
of CTOs, by a dedicated CTO operator in all participating centres, was
recommended. Chronic total occlusion recanalization techniques were
left to the discretion of the operator. Staged procedures were permitted
and encouraged for more complex cases to increase the likelihood of
complete revascularization and to decrease the risk of contrast-induced
nephropathy. Guideline-directed medical therapy included mandatory
dual antiplatelet therapy (aspirin and clopidogrel or ticagrelor or prasu-
grel) for at least 6 months, while aspirin was recommended indefinitely as
per current ESC/AHA/ACC guidelines.1,17 Strict control of LDL-C using
high-intensity statin treatment following the current guidelines and con-
trol of risk factors was recommended.1,17 The patient’s clinical status was
assessed at discharge. Hospital visits occurred at 1 month (±7 days),
6 months (±14 days), and 1 year (±30 days) post-procedure. Extended
follow-up is planned up to 5 years.
Endpoints
The primary endpoint was a composite of major adverse (patient-ori-
ented) cardiac and cerebrovascular events (MACCE) at 1-year follow-up.
Major adverse cardiac and cerebrovascular event was defined as all-cause
death, stroke, any myocardial infarction (MI) or any revascularization.
One-year MACCE was compared with a predefined PCI cohort from the
original SYNTAX-I trial. To allow for comparison, MACCE was adjudi-
cated using the same trial definitions, periprocedural MI was defined as
CK-MB >_5xULN and new pathological Q-waves in the ECG within 7 days
after PCI. Reflecting contemporary practice the definition of MI was
expanded to allow a troponin >_35 ULN (if the CK-MB was not available)
with a new pathological Q-waves in the ECG.12 Spontaneous MI was
defined as new Q-waves or one plasma level of CK-MB 5x ULN (or
Tn >_35 ULN if CK-MB not available) in the context of clinical syndrome
consistent with ACS. Secondary endpoints included (i) composite of all-
cause death, stroke, any MI at 1-year follow-up compared with the
equipoise-derived SYNTAX-I PCI cohort (safety endpoint); (ii) incidence
of the individual components of MACCE at 1-, 2-, and 5-year follow-up;
and (iii) definite stent thrombosis—according to ARC definitions at all
time points.18 As an additional exploratory endpoint the composite of
MACCE was compared with the equipoise-derived SYNTAX-I CABG
cohort of the original SYNTAX-I trial. Adverse events were adjudicated
by an independent clinical event committee.
Statistical analysis
Continuous variables are presented as mean ± standard deviation or
median [interquartile range (IQR)] and compared with the Student’s
t-test or Mann–Whitney test as appropriate. Categorical variables are
presented as counts and percentages and compared with the v2 test. The
SYNTAX-I control groups were predefined by selecting all patients from
the 3VD cohort who showed equipoise between CABG and PCI on the
basis of 4-year mortality using the SYNTAX score II calculator, resulting
in a population of 315 patients from the PCI and 334 patients from the
CABG arm. The SYNTAX score II combines age, sex, creatinine clear-
ance (ml/min), left ventricular ejection fraction (%), peripheral vascular
disease, chronic obstructive pulmonary disease, the presence of left main
disease, and the anatomical SYNTAX score. The primary endpoint was
superiority (two-sided alpha of 5%) in MACCE of the SYNTAX II group
compared with predefined patients from the original SYNTAX-I trial.
Assuming an expected rate of MACCE of 11.5% at 360 days for the EES
arm, a sample size of 450 patients was calculated to obtain a power of at
least 90% with a 5% of significance.12 The outcome analyses were per-
formed according to the intention-to treat principle and are presented as
Kaplan–Meier estimates and compared with Cox proportional hazards
models. For the primary endpoint, a sensitivity analysis using inverse
propensity score weighting (IPTW) and multivariate Cox proportional
hazard regression model were performed. As an exploratory endpoint,
non-inferiority in MACCE to the equipoise-derived SYNTAX-I CABG
cohort was investigated using a non-inferiority margin of 5% with a one-
sided alpha of 5%. The primary analysis was based on the intention-to-
treat principle. A P-value <0.05 was considered significant. The statistical
analyses were performed using the SAS System software, version 9.2
(SAS Institute Inc., SAS Campus Drive, Cary, NC, USA).
Results
The SYNTAX II strategy
Figure 1 shows the patient flow in this study. Overall, 708 patients
with de novo 3VD were screened and discussed within the heart
team. Based on the SYNTAX score II recommendation, 557 (78.7%)
patients demonstrated equipoise between CABG and PCI. After the
heart team assessment of the appropriateness of percutaneous coro-
nary revascularization, 454 patients signed written informed consent
and were included in the study. In SYNTAX I, 643 (58.8%) patients
with 3VD (without left main disease) had an equipoise recommenda-
tion for CABG or PCI based on the SYNTAX score II.
Baseline characteristics
Baseline characteristics are shown in Table 1. The mean anatomic
SYNTAX score was lower in the SYNTAX-II group compared with
equipoise-derived SYNTAX-I PCI cohort whereas the SYNTAX
score II was similar between groups (Supplementary material online,
Figure S1). In the SYNTAX II group, 298 patients (65.6%) were in the
low (0–22), 140 (30.8%) in the intermediate (23–32) and 16 (3.5%) in
the high (>32) anatomic SYNTAX score group. Staged procedures
3126 J. Escaned et al.
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were performed in 138 (30%) patients with a median of 17 days
(interquartile range 6.0–29.8).
Procedural characteristics
Physiological assessment was performed in 75.5% of the lesions
(Figure 2). The mean iFR value was 0.77 ± 0.21. Out of 1559 lesions
(3.49 ± 0.97 lesions per patient) initially intended to be treated based
on the angiographic findings, only 74.6% (2.64 ± 1.12 lesions per
patient) were found to be functionally significant. The use of coronary
physiology deferred stenting in a quarter of the lesions (25.0%,
n= 396). The iFR results based on the current cut-off of 0.89 and the
reclassification according to the FFR measurements are presented in
the Supplementary material online, Figure S2.
Post-implantation IVUS was performed in 84.1% of the patients
(76.4% of the lesions) leading to a further optimization (i.e. balloon
post-dilatation) of the stented lesion in 30.2%. The minimum stent
area post-procedure was 6.17 ± 2.31 mm2. Overall, 108 CTO’s were
attempted with a procedural success of 87%. Procedural characteris-
tics are shown in Table 2.
Optimal medical therapy
Although not specifically mandated by the protocol, ticagrelor, and
prasugrel were used in approximately one-third (33.2%) of patients;
clopidogrel therapy was used in the remaining patients. At 1 year,
60.0% of patients were on dual antiplatelet therapy (DAPT). Statins
were used in 97.3% of the patients and high-intensity statin therapy
(atorvastatin 80 mg or rosuvastatin 40 mg) was used in 80% of
patients in SYNTAX-II.
Primary endpoint and components
Table 3 and Figure 3 (panels A–F) show the MACCE and its compo-
nents at 1-year follow-up. The incidence of MACCE was significantly
lower with the SYNTAX II strategy (10.6% SYNTAX-II vs. 17.4%
equipoise-derived SYNTAX-I PCI cohort; unadjusted HR 0.58, [95%
CI 0.39–0.85], P= 0.006; adjusted HR 0.59 [95% CI 0.59–0.89],
P= 0.01; Figure 3, panel A). This difference was driven by a reduction of
73% in the incidence of any MI (Figure 3, panel E) and 43% in any revas-
cularization (Figure 3, panel F). The lower rate of MI in the SYNTAX-II
group was driven by a significant reduction in periprocedural MI. No
Figure 1 Flowchart of the study. Patients were screened on the basis of the SYNTAX score II and discussed within the heart team to assess the
appropriateness of percutaneous based revascularization; 708 patients with three-vessel (3VD) demonstrated on angiography were screened using
the SYNTAX score II by the local study coordinator and submitted to the assessment of the Heart Team who had to confirm the treatment recom-
mendation based on the SYNTAX score II. Despite equipoise in the treatment recommendation, the Heart Team recommended CABG in 42
patients; the other reasons for non-compliance to the treatment recommendation of the SYNTAX score II were: patient preference or decline par-
ticipation (n= 57) exclusion criteria (n= 11) and others (see flowchart).The 1-year clinical outcomes of patients undergoing percutaneous coronary
intervention (PCI) using the SYNTAX II strategy were compared with predefined cohorts of the PCI and CABG arm of the original SYNTAX trial.
CABG, coronary-artery bypass grafting.
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.significant difference was found in all-cause death (Figure 3, panel C)
and stroke (Figure 3, panel E) between the SYNTAX II and the
equipoise-derived SYNTAX-I PCI cohort.
There was no difference in MACCE between SYNTAX II
patients with low (<22) vs. intermediate (22–32) anatomical
SYNTAX score or in patients with or without diabetes mellitus
(Supplementary material online, Figures S3, S4). Non-hierarchical
clinical outcomes are shown in the Supplementary material
online, Table S3 and the description of the revascularization
procedures in SYNTAX II is presented in the (Supplementary
material online, Table S4). In the complete PCI cohort of
SYNTAX I trial the rate of MACCE was 17.8% at 1-year follow-
up. No difference in MACCE was found between SYNTAX II and
the equipoise-derived SYNTAX-I PCI cohort with an anatomical
SYNTAX Score >22 [HR 0.66 (95% CI 0.36 to 1.21), P= 0.179;
Supplementary material online, Figure S5]. The rate of definite
stent thrombosis was significantly lower in SYNTAX-II (HR 0.26,
95% CI 0.07–0.97, P= 0.045). A sensitivity analyses for MACCE
adjusted for confounding factors using IPTW and multivariate
Cox regression analysis confirmed these findings (Supplementary
material online, Tables S5, S6). Patients with staged procedures
were associated with a higher incidence of MACCE compared
with single-PCI [HR 2.16 (95% CI 1.15–4.05), P= 0.0071]
and similar incidence of all-cause death/stroke and MI [HR 0.96
(95% CI 0.34 to 2.70, P= 0.93); Supplementary material online,
Figure S6].
The exploratory short-term comparison with the equipoise-
derived SYNTAX-I CABG cohort suggests non-significant differences
in the occurrence of MACCE at 1 year (SYNTAX-II 10.6% vs.
equipoise-derived SYNTAX-I CABG cohort 11.2%; HR 0.91 [95% CI
0.59 to 1.14], P= 0.684) (Supplementary material online, Tables S7,
S8, and Figure S7).
Discussion
The main findings of this study can be summarized as follows: (i) PCI
undertaken using the SYNTAX II strategy was associated with supe-
rior outcomes compared with the PCI arm of the original SYNTAX-I
trial, with a lower incidence of MACCE driven by a reduction in MI,
revascularization and definite stent thrombosis at 1-year follow-up;
(ii) the short term outcomes of patients with intermediate anatomical
risk (SYNTAX score 23–32), treated with PCI using the SYNTAX
score II risk stratification algorithm, were similar to those observed in
patients with low anatomical risk (SYNTAX score <_22); (iii) physio-
logical assessment, which was feasible in 75.5% of lesions, contributed
....................................................................................................................................................................................................................
Table 1 Baseline clinical characteristics
SYNTAX II SYNTAX I PCI arm P-value
(n5 454) (n5 315)
Age (years) 66.7±9.7 (454) 66.7±9.1 (315) 0.99
Male 93.2% (423/454) 93.0% (293/315) 0.93
Body mass index (kg/m2) 28.9±4.7 (449) 28.2±4.4 (315) 0.032
Diabetes mellitus type I or II 30.3% (135/446) 29.2% (92/315) 0.75
Insulin treated 8.5% (38/446) 10.5% (33/315) 0.36
Oral medication 19.5% (87/446) 16.8% (53/315) 0.35
Diet only 2.0% (9/446) 1.9% (6/315) 0.91
Current smoker 14.7% (64/435) 17.8% (56/315) 0.26
Previous MI 12.5% (56/447) 28.7% (89/310) <0.001
Previous stroke 5.6% (25/449) 1.9% (6/315) 0.010
Hypertension 77.0% (344/447) 73.4% (229/312) 0.26
Hyperlipidaemia 77.3% (341/441) 74.4% (232/312) 0.35
Creatinine clearance (ml/min) 82.0±26.9 (454) 87.3±28.5 (315) 0.008
Ejection fraction (%) 58.1±8.3 (454) 61.8±11.3 (315) <0.001
Peripheral vascular disease 7.7% (35/454) 9.5% (30/315) 0.37
COPD 10.8% (49/454) 12.7% (40/315) 0.42
Clinical presentation <0.001
Silent ischaemia 5.5% (30/449) 13.3% (42/315)
Stable angina 68.8% (309/449) 61.6% (194/315)
Unstable angina 25.6% (115/449) 25.1% (79/315)
Anatomic SYNTAX Score 20.3±6.4 (454) 22.8±8.7 (315) <0.001
SYNTAX Score II PCI 30.2±8.6 (454) 30.6±8.7 (315) 0.528
Predicted 4-year mortality PCI (%) 8.9±8.8% (454) 9.2±8.7% (315) 0.64
SYNTAX Score II CABG 29.1±10.4 (454) 29.1±9.6 (315) 1.0
Predicted 4-year mortality CABG (%) 9.0±9.3 (454) 8.5±8.1 (315) 0.44
MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease.
3128 J. Escaned et al.
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to deferring treatment in 25% of the interrogated stenoses; (iv) the
systematic use of IVUS post-stent implantation resulted in further
stent optimization (predominantly further post-dilatation) in 30.2%
of the lesions; (v) contemporary CTO revascularization techniques
were associated with significantly improved procedural outcomes;
and (vi) in an exploratory analysis at 1-year, PCI with the SYNTAX II
strategy was associated with similar clinical outcomes to the
equipoise-derived SYNTAX-I CABG cohort.
Translation of scientific progress to clinical practice can be ham-
pered by simultaneous developments in different domains. Clinical
trials are typically designed to test the impact of a single or a reduced
number of variables on patient outcomes, using outcomes associated
with standard care as a reference. However, this approach can fail to
depict the cumulative benefit of incremental technological advances
and the application of Guideline recommended practice. The
SYNTAX II strategy was developed as representative of contempo-
rary state-of-the art of coronary revascularization. Of note, the
observed differential outcomes associated with its use cannot be
attributed to a single diagnostic or therapeutic approach but rather
to this integrated approach.
The first step of this strategy was optimizing the decision-making
process between CABG and PCI in patients with 3VD. Currently, the
European guidelines recommend CABG as the preferred revascular-
ization strategy in patients with multivessel disease (IA recommenda-
tion).1 In patients with low anatomical complexity (i.e. anatomic
SYNTAX Score < 22) percutaneous based revascularization can be
an alternative treatment (IB recommendation).1 However, beyond
the anatomical complexity, objectively quantified by the anatomic
SYNTAX score, patient‘s characteristic and comorbidities should be
taken into consideration to individualize the decision-making process
between CABG and PCI based on the long-term vital prognosis.6 In
the present study, patients were screened on the basis of the
SYNTAX score II, a clinical tool that objectively allows decision mak-
ing between CABG and PCI based on 4-year mortality. Whenever
the SYNTAX score II recommended PCI treatment or equipoise
with CABG, the patient was considered for inclusion in the trial,
patients with a recommendation for CABG were enrolled in a regis-
try. By utilizing the SYNTAX Score II, 156 patients (45%) had an ana-
tomical SYNTAX score above 22, of which 140 patients had an
anatomical SYNTAX Score 23–32. The 1-year results demonstrated
that this approach was not associated with an increase in event rates.
Within the recent EXCEL trial, investigating left main disease,
the protocol imposed an anatomic SYNTAX score >32 as a key
exclusion criteria.19 By utilizing the SYNTAX Score II, the present
study has allowed us to investigate patients with anatomically
more complex disease who, based on the current guidelines,
might not be considered initially for PCI.1 Furthermore, similar
outcomes were found in patients with low and intermediate-high
anatomical SYNTAX scores (site reported) when selected with
the SYNTAX Score II.
The use of physiology-guided revascularization has been shown to
reduce the rate of MACCE in patients with multivessel disease.11
Figure 2 Flowchart depicting ischaemia-driven revascularization in the SYNTAX II study. Physiologic evaluation of target lesions was performed
using an hybrid iFR/FFR strategy. An iFR <0.86 indicated need for revascularization, an iFR between 0.86–0.93 required decision making based on FFR
(0.80 cut-off), and an iFR >0.93 indicated deferral of PCI. iFR, instantaneous wave-free-ratio; FFR, fractional flow reserve.
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In the SYNTAX II study, and in line with the FAME trial, physiological
assessment was required in all stenoses suitable for pressure guide-
wire interrogation, irrespective of angiographic severity.20
Accordingly, mean iFR in SYNTAX II (iFR 0.77 ± 0.21) was lower
than in recent studies focused on intermediate severity stenoses
(0.91 ± 0.09 in DEFINE FLAIR).21 Physiological assessment was suc-
cessfully performed in 88% (1177/1338) of attempted stenoses
(Figure 3). In most cases the proposed hybrid iFR/FFR approach was
followed, with iFR-alone used in 829 (70.4%) cases resulting in a
reduction of the number of treated lesions from 3.49 ± 0.97 to
2.64 ± 1.12. Moreover, the physiologic interrogation of the three cor-
onary vessels performed in 82.8% of the patients decreased the num-
ber of three-vessel interventions to 37.2%. Instantaneous wave-free
ratio contributed to a simpler physiological interrogation by avoiding
the use of adenosine in 73% of the lesions assessed by coronary phys-
iology. It is quite likely that, compared with FFR-alone guidance, this
resulted in shorter procedural times.21,22 As shown in the FAME trial,
FFR-guided PCI strategy proved to be cost-effective in reducing the
....................................................................................................................................................................................................................
Table 2 Lesion and procedural characteristics and medication
SYNTAX II SYNTAX I PCI arm P-value
Lesions anatomical syntax score per patient 4.16±1.17 (454) 4.31±1.34 (315) 0.10
Lesions intended to be treated per patient 3.49±0.97 (447) 4.60±1.55 (311) <0.001
Lesions treated per patient 2.64±1.11 (440) 4.02±1.34 (311) <0.001
Stents per patient 3.78±1.92 (440) 5.19±2.04 (308) <0.001
Stents per lesion 1.43±0.76 (1165) 1.28±0.65 (1251) <0.001
Vessel assessed by physiology (iFR/FFR)
Left main 0.9% (4/447) N/A
RCA 86.4% (386/447) N/A
LAD 98.9% (442/447) N/A
LCX 96.0% (429/447) N/A
Assessment in three vessels 82.8% (370/447)
Vessel treated
Left main 0.9% (4/441) 2.3% (7/311) 0.22
RCA 60.5% (267/441) 87.1% (271/311) <0.001
LAD 92.5% (408/441) 99.0% (308/311) <0.001
LCX 67.1% (296/441) 96.5% (300/311) <0.001
Treatment in three vessels 37.2% (164/441) 83.3% (259/311) <0.001
Mean stent length (per stent, mm) 24.43±9.18 (1663) 18.82±7.04 (1599) <0.001
Total stent length (per patient, mm) 92.32±52.78 (440) 97.71±43.66 (308) 0.13
Bifurcation treated (%) 35.0% (159/454) 60.6% (191/315) <0.001
Total occlusion treated (%) 27.8% (126/453) 28.3% (89/315) 0.88
Post-implantation IVUS MLA (mm2) 6.17±2.31 (1094) N/A
Medications
Aspirin
At discharge 99.8% (448/449) 96.2% (302/314) <0.001
At 1 month 99.6% (443/445) 93.9% (292/311) <0.001
At 1 year 95.6% (413/432) 92.1% (278/302) 0.046
P2Y12 inhibitor
At discharge 99.3% (446/449) 98.4% (309/314) 0.234
Clopidogrel 66.8% (298/446) N/A
Prasugrel 4.5% (20/446) N/A
Ticagrelor 28.7% (128/446) N/A
At 1 month 99.6% (443/445) 97.1% (302/311) 0.004
Clopidogrel 66.8% (298/446) N/A
Prasugrel 4.5% (20/446) N/A
Ticagrelor 28.7% (128/446) N/A
At 1 year DAPT 61.8% (267/432) 72.2% (218/302) 0.0034
Beta-blocker at discharge 75.7% (339/448) 77.1% (242/314) 0.66
Statin at discharge 97.3% (437/449) 85.4% (268/314) <0.001
DAPT, dual antiplatelet therapy; IVUS, intravascular ultrasound; FFR, fractional flow reserve; iFR, Instantaneous wave-free ratio; MLA, minimum lumen area; LAD, left anterior
descending artery; LCX, left circumflex; RCA, right coronary artery.
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number of stented lesions.23 In addition, iFR spares the use of adeno-
sine and is time saving which may also result in cost saving.
Together with optimized implant technique, the thin-strut biore-
sorbable polymer DES used in the present study is probably respon-
sible for the observed reduction in stent thrombosis, MI, and
revascularization. In a network meta-analysis by Palmerini et al.,9 con-
temporary metallic DES were found to be superior to the thick strut
permanent polymer paclitaxel-eluting stent (PES) used in SYNTAX
(Taxus, Boston Scientific). Paclitaxel-eluting stent was associated with
sustained vessel wall toxicity, and greater on-going risk for very late
stent thrombosis compared with newer generation DES.9,24 Also, in
agreement with previous studies, post-procedural IVUS guidance
may have contributed to a improved stent implantation and a reduc-
tion in device-related adverse events such as revascularization and
stent thrombosis.10 The use of second-generation DES in the context
of patients with 3VD was investigated in the BEST trial. Patients were
randomized to CABG or PCI with a thin-strut durable polymer DES
(Xience, Abbott Vascular, USA).4 At 1 year, the MACCE rate in the
PCI arm of BEST was 11.4% which is similar to the 10.6% observed in
the present study. The number and the length of the stents placed
were similar between BEST and SYNTAX II, and the proportion of
IVUS used was also comparable (71% in BEST and 84.1% in SYNTAX
II). Notably, in the BEST trial no difference in MACCE between
CABG and PCI was observed at 1 year; however, at 5 years CABG
was associated with a significant reduction in the cumulative inci-
dence of adverse cardiac events (21.1% PCI vs. 14.6% CABG,
P= 0.01). In concordance with the BEST trial, we found no difference
in the rates of MACCE at 1 year between CABG and PCI but we
recognize the superiority of CABG over PCI might become apparent
over a longer period of follow-up.25,26
In SYNTAX II the procedural success rate of CTO recanalization
was 87%, similar to that recently reported by dedicated European
CTO operators.27 The difference in procedural success compared
with that observed in CTOs in SYNTAX-I trial (i.e. 53%) can be
explained by the evolution in CTO revascularization techniques, cor-
onary wires and devices, and the increased systematization of the
procedure.
Overall, the initial results of SYNTAX II provide evidence of the
impact of the technological developments in the field of PCI in clinical
outcomes. The plan is to follow this cohort for 5 years to facilitate
understanding of whether lesion deferral in patients with 3VD is safe
in the long-term; and whether the non-inferiority of PCI using the
SYNTAX II strategy compared with CABG is maintained.
Limitations
The present study has several limitations. First, this is a non-
randomized study comparing a contemporary strategy with a historical
control group (SYNTAX-I). This study was designed to investigate a
novel approach for selecting and treating patients, based on long-term
(4 years) prognosis and suggests that treatment of selected patients
with an anatomical SYNTAX score >22 is not associated with a higher
risk of MACCE at 1 year. Because of the observed advantage of CABG
in females and young patients, the SYNTAX score II as a screening tool
resulted in a low proportion of these subgroups of patients in the cur-
rent study. Second, the exclusion of patients with previous PCI, who
represent a large proportion of current clinical practice, might impair
....................................................................................................................................................................................................................
Table 3 One year clinical outcomes between SYNTAX II cohort and the equipoise-derived SYNTAX-I PCI
Outcome SYNTAX II (n5 454) SYNTAX I PCI arm (n5 315) Hazard ratio (95% CI) P-value
MACCE, % (n) 10.6% (47) 17.4% (54) 0.58 (0.39–0.85) 0.006
All-cause death, stroke and any MI, % (n) 3.8% (17) 6.4% (20) 0.58 (0.30–1.10) 0.09
All-cause death, % (n) 2.0% (9) 2.9% (9) 0.69 (0.27–1.73) 0.43
Cardiac death, % (n) 1.1% (5) 2.6% (8) — 0.13
Vascular death, % (n) 0.2% (1) 0.0% (0) — 0.41
Non-cardiovascular death, % (n) 0.7% (3) 0.3% (1) — 0.52
Stroke, % (n) 0.4% (2) 0.7% (2) 0.69 (0.10–4.89) 0.71
Ischaemic, % (n) 0.4% (2) 0.3% (1) — 0.79
Haemorrhagic, % (n) 0.2% (1) 0.3% (1) — 0.80
Any MI, % (n) 1.4% (6) 4.8% (15) 0.27 (0.11–0.70) 0.007
Periprocedural MI, % (n) 0.2% (1) 3.8% (12) — <0.001
Spontaneous MI, % (n) 1.1% (5) 1.0% (3) — 0.880
Any revascularization, % (n) 8.2% (36) 13.7% (42) 0.57 (0.37–0.90) 0.015
CABG, % (n) 0.7% (3) 1.6% (5) — 0.21
PCI, % (n) 7.5% (33) 12.5% (38) — 0.022
Definite stent thrombosis, % (n) 0.7% (3) 2.6% (8) 0.26 (0.07–0.97) 0.045
Acute, % (n) 0.2% (1) 1.6% (5) — 0.40
Sub-acute, % (n) 0.0% (0) 1.6% (5) — 0.007
Late, % (n) 0.5% (2) 1.0% (3) — 0.37
Probable stent thrombosis, % (n) 0.2% (1) NA —
The event rates are based on Kaplan–Meier estimates.
MACCE, major adverse cardiac and cerebrovascular events (any death, any stroke, any MI and any revascularization); MI, myocardial infarction; CABG, coronary artery bypass
graft.
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the generalizability of these findings. Third, for the comparison with the
original SYNTAX-I trial a temporal bias should be acknowledged as
surgical techniques may have improved together with adjunctive medi-
cal therapy. Fourth, 6 out of the 30 adjudicated revascularization events
were due to reintervention at the CTO location (i.e. post-dilatation
and additional stent implantation) to adapt the stent to the vessel vaso-
dilation seen after the restoration of coronary flow at the index PCI
procedure.28 Although these non-ischaemic driven reinterventions
may not be perceived as true revascularization events, they were adju-
dicated as revascularization events to respect the protocol definition
of all cause revascularization (Supplementary material online, Figure
S4). Fifth, the definition of spontaneous MI used in SYNTAX-II did not
result in lower rates of MI compared with the third universal definition
of MI; however, we have to acknowledge that the SYNTAX definition
Figure 3 One-year clinical outcomes among the study patients, compared with the equipoise-derived SYNTAX-I PCI cohort. Kaplan–Meier
curves are shown for the SYNTAX-II group (blue) and the percutaneous coronary intervention (PCI) arm of the original SYNTAX-I trial (red) for
the composite primary endpoint of major adverse cardiac or cerebrovascular events (MACCE, panel A), all-cause death/stroke/MI (panel B), all cause
death (panel C); stroke (panel D); any myocardial infarction (panel E); any revascularization (panel F).
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of spontaneous MI might be less sensitive compared with the third uni-
versal definition of MI.29 Sixth, although we have used several statistical
methods to attempt to ensure balance between the groups we
acknowledge that it is not possible to adjust for every potential con-
founder. Seventh, although the use of coronary physiology was manda-
tory in lesions intended to be treated, mild stenoses not included in
the anatomic SYNTAX score which could potentially be associated
with reduced FFR were not systematically assessed by iFR/FFR.11
Finally, regarding the IVUS analysis, we only provided the site-reported
minimum stent area post-procedure; an ongoing core lab analysis will
provide a further insight into the IVUS data within this study.
Conclusion
At 1 year, clinical outcomes with the SYNTAX-II strategy were asso-
ciated with improved clinical results compared with the PCI per-
formed in comparable patients from the original SYNTAX-I trial.
Longer term follow-up is awaited and a randomized clinical trial with
contemporary CABG is warranted.
Supplementary material
Supplementary material is available at European Heart Journal online.
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